Comparing Cumberland Pharmaceuticals (NASDAQ:CPIX) and Marker Therapeutics (NASDAQ:MRKR)

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Valuation and Earnings

This table compares Cumberland Pharmaceuticals and Marker Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$37.87 million	1.36	-$6.48 million	($0.22)	-15.64
Marker Therapeutics	$6.59 million	1.87	-$10.73 million	($1.37)	-0.70

Cumberland Pharmaceuticals has higher revenue and earnings than Marker Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cumberland Pharmaceuticals and Marker Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-6.97%	7.48%	2.66%
Marker Therapeutics	-271.12%	-114.59%	-90.31%

Insider and Institutional Ownership

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 44.9% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 7.8% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Cumberland Pharmaceuticals has a beta of -0.37, indicating that its stock price is 137% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cumberland Pharmaceuticals and Marker Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	0	0	0	0	0.00
Marker Therapeutics	0	0	2	2	3.50

Marker Therapeutics has a consensus price target of $13.17, suggesting a potential upside of 1,279.29%. Given Marker Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Cumberland Pharmaceuticals.

Summary

Marker Therapeutics beats Cumberland Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.